Nxera Pharma Co., Ltd.

OTCPK:SOLT.F Stock Report

Market Cap: US$708.2m

Nxera Pharma Management

Management criteria checks 4/4

Nxera Pharma's CEO is Chris Cargill, appointed in Mar 2022, has a tenure of 4.5 years. total yearly compensation is ¥273.00M, comprised of 46.5% salary and 53.5% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $1.02M. The average tenure of the management team and the board of directors is 2.8 years and 4 years respectively.

Key information

Chris Cargill

Chief executive officer

JP¥273.0m

Total compensation

CEO salary percentage46.52%
CEO tenure4.5yrs
CEO ownership0.1%
Management average tenure2.8yrs
Board average tenure4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Cargill's remuneration changed compared to Nxera Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-JP¥8b

Mar 31 2026n/an/a

-JP¥10b

Dec 31 2025JP¥273mJP¥127m

-JP¥13b

Sep 30 2025n/an/a

-JP¥6b

Jun 30 2025n/an/a

-JP¥3b

Mar 31 2025n/an/a

-JP¥2b

Dec 31 2024JP¥358mJP¥115m

-JP¥5b

Sep 30 2024n/an/a

-JP¥4b

Jun 30 2024n/an/a

-JP¥10b

Mar 31 2024n/an/a

-JP¥9b

Dec 31 2023JP¥312mJP¥101m

-JP¥7b

Sep 30 2023n/an/a

-JP¥3b

Jun 30 2023n/an/a

JP¥2b

Mar 31 2023n/an/a

JP¥1b

Dec 31 2022JP¥292mJP¥88m

JP¥382m

Sep 30 2022n/an/a

-JP¥383m

Jun 30 2022n/an/a

-JP¥224m

Mar 31 2022n/an/a

JP¥100m

Dec 31 2021JP¥231mJP¥65m

JP¥1b

Sep 30 2021n/an/a

JP¥1b

Jun 30 2021n/an/a

JP¥1b

Mar 31 2021n/an/a

JP¥1b

Dec 31 2020JP¥157mJP¥53m

JP¥1b

Sep 30 2020n/an/a

-JP¥2b

Jun 30 2020n/an/a

-JP¥1b

Mar 31 2020n/an/a

-JP¥332m

Dec 31 2019JP¥101mJP¥40m

JP¥1b

Compensation vs Market: Chris's total compensation ($USD1.78M) is below average for companies of similar size in the US market ($USD3.51M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Cargill (42 yo)

4.5yrs
Tenure
JP¥273,000,000
Compensation

Mr. Christopher Cargill, also known as Chris, serves as Representative Executive Officer, President, Chief Executive Officer and Director at Nxera Pharma Co., Ltd. (formerly known as Sosei Group Corporatio...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Cargill
Representative Executive Officer4.5yrsJP¥273.00m0.14%
$ 1.0m
Hironoshin Nomura
Executive Officer & CFO4.5yrsJP¥112.00m0.012%
$ 81.8k
Shinichi Tamura
Founderno dataJP¥332.00mno data
Toshihiro Maeda
President of Nxera Pharma Japan & COO2.8yrsno datano data
Kieran Johnson
Executive Officer & Chief Accounting Officer4.5yrsJP¥109.00mno data
Patrik Foerch
Chief Scientific Officerless than a yearno datano data
Shinya Tsuzuki
Head of Investor Relations1.3yrsno datano data
Mariko Nakafuji
Executive VP & Chief Legal Officer1.4yrsno datano data
Shinichiro Nishishita
VP of Investor Relations & Head of Regulatory Disclosuresno datano datano data
Stacey Southall
Associate Director & Head of Biophysicsno datano datano data
Candelle Chong
Executive Officer3.5yrsJP¥108.00mno data
Patrick Branch
Head of Business Development for Japan and the APAC region2.4yrsno datano data
2.8yrs
Average Tenure
43yo
Average Age

Experienced Management: SOLT.F's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Cargill
Representative Executive Officer4.5yrsJP¥273.00m0.14%
$ 1.0m
Malcolm Weir
Member of Scientific Advisory Board3yrsJP¥134.00mno data
Rolf Kristian Berndtson Soderstrom
Independent External Director6.5yrsno data0.022%
$ 159.1k
Noriaki Nagai
Member of Advisory Boardless than a yearno data0.040%
$ 285.1k
David Roblin
Independent External Director8.3yrsno data0.014%
$ 98.8k
Paul Leeson
Member of Scientific Advisory Boardno datano datano data
Peter Bernstein
Member of Scientific Advisory Boardno datano datano data
Richard Henderson
Member of Scientific Advisory Boardno datano datano data
Chris Tate
Member of Scientific Advisory Boardno datano datano data
John Parkinson
Member of Scientific Advisory Board4.7yrsno datano data
Eiko Tomita
Independent External Director3.4yrsno data0.011%
$ 76.6k
Nicola Rabson
Outside Independent Director1.5yrsno datano data
4.0yrs
Average Tenure
61yo
Average Age

Experienced Board: SOLT.F's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/09 22:29
End of Day Share Price 2026/09/09 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nxera Pharma Co., Ltd. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Koichi MameganoBofA Global Research
Hidemaru YamaguchiCitigroup Inc
Kazuaki HashiguchiDaiwa Securities Co. Ltd.